[go: up one dir, main page]

SG11201907038WA - Quinazoline compound - Google Patents

Quinazoline compound

Info

Publication number
SG11201907038WA
SG11201907038WA SG11201907038WA SG11201907038WA SG11201907038WA SG 11201907038W A SG11201907038W A SG 11201907038WA SG 11201907038W A SG11201907038W A SG 11201907038WA SG 11201907038W A SG11201907038W A SG 11201907038WA SG 11201907038W A SG11201907038W A SG 11201907038WA
Authority
SG
Singapore
Prior art keywords
lung cancer
compound
quinazoline compound
present
pharmaceutical composition
Prior art date
Application number
SG11201907038WA
Inventor
Kazuyuki Kuramoto
Michinori Akaiwa
Tomoaki Abe
Takanobu Araki
Susumu Yamaki
Shigeki Kunikawa
Tomoyoshi Imaizumi
Takahiro Nigawara
Keisuke Arakawa
Itsuro Shimada
Masashi Shimazaki
Yoshiki Satake
Kazushi Watanabe
Takanori Koike
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG11201907038WA publication Critical patent/SG11201907038WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Abstract] [Problem] 5 Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a 10 quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer. [Selected Figure] Nil
SG11201907038WA 2017-02-02 2018-02-01 Quinazoline compound SG11201907038WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017017266 2017-02-02
JP2017143607 2017-07-25
PCT/JP2018/003323 WO2018143315A1 (en) 2017-02-02 2018-02-01 Quinazoline compound

Publications (1)

Publication Number Publication Date
SG11201907038WA true SG11201907038WA (en) 2019-08-27

Family

ID=63040813

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907038WA SG11201907038WA (en) 2017-02-02 2018-02-01 Quinazoline compound

Country Status (21)

Country Link
US (2) US10556906B2 (en)
EP (1) EP3578560B1 (en)
JP (1) JP6587116B2 (en)
KR (1) KR20190113799A (en)
CN (1) CN110267957B (en)
AU (1) AU2018216411A1 (en)
BR (1) BR112019015364A2 (en)
CA (1) CA3052125A1 (en)
CO (1) CO2019008487A2 (en)
ES (1) ES2899871T3 (en)
IL (1) IL268190A (en)
JO (1) JOP20190186A1 (en)
MA (1) MA47433A (en)
MX (1) MX2019009187A (en)
PH (1) PH12019501685A1 (en)
PL (1) PL3578560T3 (en)
PT (1) PT3578560T (en)
RU (1) RU2019123529A (en)
SG (1) SG11201907038WA (en)
TW (1) TW201838996A (en)
WO (1) WO2018143315A1 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
CA2981530A1 (en) 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (en) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー Fused hetero-heterobicyclic compounds and methods of use thereof
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110869357A (en) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Compounds and methods of use thereof for treating cancer
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10689377B2 (en) 2017-11-15 2020-06-23 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW202012415A (en) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 Chemical compounds
JP2021176819A (en) * 2018-07-31 2021-11-11 アステラス製薬株式会社 Pharmaceutical composition comprising quinazoline compound as active ingredient
JP2021176820A (en) * 2018-07-31 2021-11-11 アステラス製薬株式会社 Pharmaceutical composition comprising quinazoline compound as active ingredient
JP2021532157A (en) 2018-08-01 2021-11-25 アラクセス ファーマ エルエルシー Heterocyclic spiro compounds for treating cancer and how to use them
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
AU2019340366B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
JP7628305B2 (en) * 2018-10-24 2025-02-10 アラクセス ファーマ エルエルシー 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis - Patents.com
WO2020085493A1 (en) * 2018-10-26 2020-04-30 大鵬薬品工業株式会社 Novel indazole compound or salt thereof
CN113227092A (en) * 2018-11-29 2021-08-06 亚瑞克西斯制药公司 Compounds and methods of use thereof for treating cancer
JP7592601B2 (en) * 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド KRAS G12C inhibitors
CN111499634B (en) * 2019-01-31 2023-05-12 贝达药业股份有限公司 Quinazoline compound and application thereof in medicine
EP3924053A1 (en) 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
WO2020177629A1 (en) * 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 Spiro-substituted pyrimidine-fused cyclic compound, preparation method therefor and medical use thereof
WO2020207483A1 (en) * 2019-04-10 2020-10-15 南京明德新药研发有限公司 Crystal form of egfr inhibitor and preparation method therefor
AU2020260629A1 (en) * 2019-04-22 2021-12-09 Betta Pharmaceuticals Co., Ltd Quinazoline compound and pharmaceutical application thereof
JP7502337B2 (en) * 2019-05-20 2024-06-18 カリフォルニア インスティチュート オブ テクノロジー KRAS G12C INHIBITORS AND USES THEREOF
CN112110918B (en) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 Spiro substituted pyrimido cyclic compounds, process for their preparation and their use in medicine
WO2020259573A1 (en) * 2019-06-25 2020-12-30 南京明德新药研发有限公司 Seven-membered heterocyclic derivative acting as kras g12c mutant protein inhibitor
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
JP2022548791A (en) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド combination therapy
JP7340100B2 (en) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Small Molecule Inhibitor of KRAS G12C Mutant
CN114867735A (en) 2019-11-04 2022-08-05 锐新医药公司 RAS inhibitors
CR20220241A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc RAS INHIBITORS
CN114901366A (en) 2019-11-04 2022-08-12 锐新医药公司 RAS inhibitors
CN112851663B (en) * 2019-11-12 2023-07-18 博瑞生物医药（苏州）股份有限公司 Parallel heterocyclic compound and application thereof
WO2021093758A1 (en) * 2019-11-15 2021-05-20 四川海思科制药有限公司 Pyrimido derivative and application thereof in medicine
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
BR112022012106A2 (en) 2019-12-20 2022-09-20 Mirati Therapeutics Inc SOS1 INHIBITORS
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CA3162106A1 (en) * 2019-12-27 2021-07-01 Yuli Xie Spiro ring-containing quinazoline compound
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
TW202140450A (en) * 2020-02-24 2021-11-01 大陸商泰勵生物科技（上海）有限公司 Kras inhibitors useful for the treatment of cancers
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN114845997B (en) * 2020-02-24 2024-03-29 上海喆邺生物科技有限公司 Aromatic compound and application thereof in preparation of antitumor drugs
CA3170068A1 (en) * 2020-03-25 2021-09-30 Yuli Xie Spiro ring-containing quinazoline compound
CN115697994B (en) * 2020-06-10 2024-08-13 江苏恒瑞医药股份有限公司 Fused quinazoline derivative, preparation method thereof and application thereof in medicine
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
BR112023004569A2 (en) 2020-09-11 2023-04-04 Mirati Therapeutics Inc CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
WO2022063297A1 (en) * 2020-09-27 2022-03-31 微境生物医药科技(上海)有限公司 Quinazoline derivative, preparation method therefor and use thereof
CN116323624A (en) * 2020-09-30 2023-06-23 上海医药集团股份有限公司 Quinazoline compound and application thereof
WO2022083616A1 (en) * 2020-10-21 2022-04-28 贝达药业股份有限公司 Quinazoline compound and pharmaceutical composition thereof
CN112341351B (en) * 2020-10-27 2022-03-11 无锡双启科技有限公司 Preparation method of 2-amino-4-bromo-3-fluoro-5-iodobenzamide
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
CN115803328B (en) * 2020-11-24 2024-07-23 成都百裕制药股份有限公司 Piperazine-2, 3-dione derivatives and their use in medicine
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
AU2021407653B9 (en) * 2020-12-22 2025-06-05 Shanghai Kechow Pharma, Inc Preparation and application method of heterocyclic compound as kras inhibitor
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITOR AND ITS USE
WO2022152313A1 (en) * 2021-01-18 2022-07-21 成都百裕制药股份有限公司 Pyrimidine derivative and pharmaceutical application thereof
JP2024506329A (en) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド Heterocyclic compounds and their uses
CN116783194A (en) * 2021-02-09 2023-09-19 微境生物医药科技(上海)有限公司 Quinazoline derivatives containing spiro rings
AU2022219124A1 (en) * 2021-02-09 2023-08-31 Usynova Pharmaceuticals Ltd. Pyrimidine aromatic ring compounds
PE20240235A1 (en) * 2021-02-15 2024-02-16 Astellas Pharma Inc QUINAZOLINE COMPOUND TO INDUCE THE DEGRADATION OF THE KRAS MUTANT G12D PROTEIN
US20240150366A1 (en) * 2021-02-15 2024-05-09 Astellas Pharma Inc. 4-aminoquinazoline compound
CN115124524A (en) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 Tricyclic derivative and preparation method and application thereof
WO2022232318A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CN118234731A (en) 2021-05-05 2024-06-21 锐新医药公司 RAS inhibitors
CA3217920A1 (en) 2021-05-05 2022-11-10 Andreas BUCKL Ras inhibitors for the treatment of cancer
WO2022247760A1 (en) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
JP2024520000A (en) * 2021-05-24 2024-05-21 上海瓔黎薬業有限公司 Nitrogen-containing heterocyclic compounds, their production method and use
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202317100A (en) 2021-06-23 2023-05-01 瑞士商諾華公司 Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
WO2023008462A1 (en) 2021-07-27 2023-02-02 東レ株式会社 Medicament for treatment and/or prevention of cancer
IL309086A (en) 2021-09-01 2024-02-01 Novartis Ag Pharmaceutical combinations involving a tonic inhibitor and its uses for the treatment of cancer
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN117222646A (en) * 2021-09-16 2023-12-12 苏州赞荣医药科技有限公司 KRAS G12C inhibitors and uses thereof
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
JP2025500878A (en) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション PYRAZOLO-PYRAZINE COMPOUNDS AS SHP2 INHIBITORS
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
WO2023119677A1 (en) * 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
WO2023138662A1 (en) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 Benzopyrimidine compounds and use thereof
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
MX2024011056A (en) * 2022-03-11 2024-09-18 Astellas Pharma Inc Heterocyclic compound for inducing degradation of g12d mutant kras protein.
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
KR20250022133A (en) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. macrocyclic RAS inhibitors
EP4567033A1 (en) * 2022-08-05 2025-06-11 Astellas Pharma Inc. Heterocyclic compound for inducing degradation of mutant kras protein
CN119768398A (en) 2022-08-09 2025-04-04 安斯泰来制药有限公司 Heterocyclic compounds which inhibit and/or induce KRAS protein degradation
WO2024034593A1 (en) * 2022-08-09 2024-02-15 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of g12v mutant kras protein
WO2024034123A1 (en) * 2022-08-12 2024-02-15 アステラス製薬株式会社 Pharmaceutical composition containing heterocyclic compound
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024188281A1 (en) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 Compound having quinazoline structure and use thereof
TW202504611A (en) 2023-03-30 2025-02-01 美商銳新醫藥公司 Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (en) 2023-04-07 2025-06-18 Revolution Medicines Inc RAS INHIBITORS
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502779A (en) 2023-06-30 2025-01-16 美商金橘生物科技公司 Substituted heteroaromatic amines and uses thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025052649A1 (en) 2023-09-08 2025-03-13 アステラス製薬株式会社 Method for selective production of single axially chiral compound
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379563B (en) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 Composition and method for treating cancer
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
CA2981530A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10414757B2 (en) * 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof

Also Published As

Publication number Publication date
US10556906B2 (en) 2020-02-11
EP3578560B1 (en) 2021-11-10
IL268190A (en) 2019-10-31
JOP20190186A1 (en) 2019-08-01
US20200140437A1 (en) 2020-05-07
JPWO2018143315A1 (en) 2019-08-08
EP3578560A4 (en) 2020-10-21
CN110267957A (en) 2019-09-20
PH12019501685A1 (en) 2020-06-01
BR112019015364A2 (en) 2020-03-10
CN110267957B (en) 2022-04-26
MX2019009187A (en) 2019-09-26
US20190292182A1 (en) 2019-09-26
EP3578560A1 (en) 2019-12-11
RU2019123529A (en) 2021-03-02
PT3578560T (en) 2021-12-13
AU2018216411A1 (en) 2019-08-15
US10774082B2 (en) 2020-09-15
ES2899871T3 (en) 2022-03-15
KR20190113799A (en) 2019-10-08
PL3578560T3 (en) 2022-01-17
CA3052125A1 (en) 2018-08-09
MA47433A (en) 2019-12-11
JP6587116B2 (en) 2019-10-09
TW201838996A (en) 2018-11-01
CO2019008487A2 (en) 2019-08-20
WO2018143315A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
SG11201907038WA (en) Quinazoline compound
SA520411982B1 (en) Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) Inhibitors And Their Use for Treatment of Cancer
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2024007853A (en) Pharmaceutical composition comprising a quinazoline compound.
MX2019013954A (en) KRAS COVALENT INHIBITORS.
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
PH12018501920B1 (en) Bromodomain inhibitors
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
MX2020001717A (en) Macrocyclic mcl-1 inhibitors and methods of use.
MX2020001719A (en) Macrocyclic mcl-1 inhibitors and methods of use.
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
MX2023002507A (en) Cd73 inhibitors.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2019008808A (en) Pyrimidine compound and pharmaceutical use thereof.
ZA202204941B (en) Cd73 inhibitors
MX2021010297A (en) Human plasma kallikrein inhibitors.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
EA035519B9 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2019004375A (en) Bromodomain inhibitors.
PH12017501668A1 (en) Bace1 inhibitors
MX2019004187A (en) Bromodomain inhibitors.
MX2020008273A (en) Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same.